Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with advanced chronic kidney disease, dialysis, or kidney transplantation
2021-001520-18Phase 4Completed
- Sponsor
- RECOVAC Consortium
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran, ChAdOx1 nCoV-19 and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by RECOVAC Consortium. Primary endpoint: Incidence of COVID-19 over two years after SARS-CoV-2 vaccination. Started Mar 2021; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001520-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001520-18.